When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer

References

• BrawleyOWProstate cancer epidemiology in the United StatesWorld J Urol201230219520022476558
   PubMed Web of Science ®Google Scholar
• CrawfordEDEpidemiology of prostate cancerUrology2003626 Suppl 131214706503
   PubMed Web of Science ®Google Scholar
• PunnenSCooperbergMRThe epidemiology of high-risk prostate cancerCurr Opin Urol Epub4242013
   Web of Science ®Google Scholar
• SolowayMSHardemanSWHickeyDStratification of patients with metastatic prostate cancer based on extent of disease on initial bone scanCancer19886111952023334948
   PubMed Web of Science ®Google Scholar
• OhmoriKMatsuiHYasudaTEvaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigramsJpn J Clin Oncol19972742632679379516
   PubMed Web of Science ®Google Scholar
• SabbatiniPLarsonSMKremerAPrognostic significance of extent of disease in bone in patients with androgen-independent prostate cancerJ Clin Oncol199917394895710071289
   PubMed Web of Science ®Google Scholar
• RigaudJTiguertRLe NormandLPrognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapyJ Urol20021684 Pt 11423142612352409
   PubMed Web of Science ®Google Scholar
• ChengHHLinDWYuEYAdvanced clinical states in prostate cancerUrol Clin North Am201239456157123084531
   PubMed Web of Science ®Google Scholar
• TanakaNFujimotoKShinkaiTBone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/mL and Gleason score of <=6 at the initial stage of diagnosisJpn J Clin Oncol201141101209121321862505
   PubMed Web of Science ®Google Scholar
• MoslehiMChekiMSalehi-MarzijaraniMAmuchasteguiTGholamrezanezhadAPredictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancerRev Esp Med Nucl Imagen Mol Epub382013
   Web of Science ®Google Scholar
• LongMAHusbandJEFeatures of unusual metastases from prostate cancerBr J Radiol19997286293394110673942
   PubMed Web of Science ®Google Scholar
• ReigmanHIStokkelMPPeripheral bone metastases in prostate cancer: a rare localization at initial presentationClin Nucl Med200429533533615069341
   PubMed Web of Science ®Google Scholar
• TombalBLecouvetFModern detection of prostate cancer’s bone metastasis: is the bone scan era over?Adv Urol2012201289319322013439
   PubMedGoogle Scholar
• HorwichAHugossonJde ReijkeTWiegelTFizaziKKatajaVProstate cancer: ESMO Consensus Conference Guidelines 2012Ann Oncol20132451141116223303340
   PubMed Web of Science ®Google Scholar
• Mari ApariciCSeoYFunctional imaging for prostate cancer: therapeutic implicationsSemin Nucl Med201242532834222840598
   PubMed Web of Science ®Google Scholar
• KhokherMADandonaPDiphosphonates inhibit human osteoblast secretion and proliferationMetabolism19893821841872521525
   PubMed Web of Science ®Google Scholar
• Even-SapirEMetserUMishaniELievshitzGLermanHLeibovitchIThe detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CTJ Nucl Med200647228729716455635
   PubMed Web of Science ®Google Scholar
• LangstegerWHaimSKnauerMImaging of bone metastases in prostate cancer: an updateQ J Nucl Med Mol Imaging201256544745823069924
   PubMed Web of Science ®Google Scholar
• DamleNABalCBandopadhyayaGPThe role of (18)F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and (99m) Tc-MDP bone scanJpn J Radiol201331426226923377765
   PubMed Web of Science ®Google Scholar
• WithofsNGrayetBTancrediT18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancersNucl Med Commun201132316817621076343
   PubMed Web of Science ®Google Scholar
• MachedaMLRogersSBestJDMolecular and cellular regulation of glucose transporter (GLUT) proteins in cancerJ Cell Physiol2005202365466215389572
   PubMed Web of Science ®Google Scholar
• SmithTAMammalian hexokinases and their abnormal expression in cancerBr J Biomed Sci200057217017810912295
   PubMed Web of Science ®Google Scholar
• JadvarHXiankuiLShahinianAGlucose metabolism of human prostate cancer mouse xenograftsMol Imaging200542919716105512
   PubMedGoogle Scholar
• ShrevePDGrossmanHBGrossMDWahlRLMetastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucoseRadiology199619937517568638000
   PubMed Web of Science ®Google Scholar
• YehSDImbriacoMLarsonSMDetection of bony metastases of androgen-independent prostate cancer by PET-FDGNucl Med Biol19962366936978940712
   PubMed Web of Science ®Google Scholar
• MorrisMJAkhurstTOsmanIFluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerUrology200259691391812031380
   PubMed Web of Science ®Google Scholar
• AckerstaffEPflugBRNelsonJBBhujwallaZMDetection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cellsCancer Res20016193599360311325827
   PubMed Web of Science ®Google Scholar
• SutinenENurmiMRoivainenAKinetics of [(11)C]choline uptake in prostate cancer: a PET studyEur J Nucl Med Mol Imaging200431331732414628097
   PubMed Web of Science ®Google Scholar
• BoucheloucheKTagawaSTGoldsmithSJTurkbeyBCapalaJChoykePPET/CT imaging and radioimmunotherapy of prostate cancerSemin Nucl Med2011411294421111858
   PubMed Web of Science ®Google Scholar
• EvangelistaLZattoniFGuttillaACholine PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysisClin Nucl Med201338530531423486334
   PubMed Web of Science ®Google Scholar
• BeheshtiMValiRWaldenbergerPDetection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative studyEur J Nucl Med Mol Imaging200835101766177418465129
   PubMed Web of Science ®Google Scholar
• BeheshtiMValiRWaldenbergerPThe use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CTMol Imaging Biol20101219810719588206
   PubMed Web of Science ®Google Scholar
• BeheshtiMImamovicLBroingerG18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patientsRadiology2010254392593320177103
   PubMed Web of Science ®Google Scholar
• TuncelMSouvatzoglouMHerrmannK[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancerNucl Med Biol200835668969518678354
   PubMed Web of Science ®Google Scholar
• UmbehrMHMüntenerMHanyTSulserTBachmannLMThe role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysisEur Urol Epub4192013
   Web of Science ®Google Scholar
• Al-TamimiATanAEKwongSYSamCCChongATanCHFalse-negative bone scan and choline PET/CT study in a case of prostate cancer: the pitfall of the small cell prostate carcinoma variantWorld J Nucl Med2012112757823372441
   PubMedGoogle Scholar
• GiovacchiniGGajateAMMessaCFazioFIncreased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancerClin Nucl Med2008331179779818936620
   PubMed Web of Science ®Google Scholar
• SchirrmeisterHGuhlmannAElsnerKSensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PETJ Nucl Med199940101623162910520701
   PubMed Web of Science ®Google Scholar
• HetzelMArslandemirCKönigHHF-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient managementJ Bone Miner Res200318122206221414672356
   PubMed Web of Science ®Google Scholar
• KrügerSBuckAKMottaghyFMDetection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CTEur J Nucl Med Mol Imaging200936111807181219504092
   PubMed Web of Science ®Google Scholar
• LiYSchiepersCLakeRDadparvarSBerenjiGRClinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseasesBone201250112813922001678
   PubMed Web of Science ®Google Scholar
• TateishiUMoritaSTaguriMA meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumorAnn Nucl Med201024752353120559896
   PubMed Web of Science ®Google Scholar
• LangstegerWBalogovaSHuchetVFluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked readingQ J Nucl Med Mol Imaging201155444845721738117
   PubMed Web of Science ®Google Scholar
• [No authors listed]Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA)Oncology (Williston Park)2000142267272277278280 passim10736812
   PubMed Web of Science ®Google Scholar
• American Urological AssociationProstate-specific antigen (PSA) best practice statement: 2009 update Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdfAccessed April 23, 2013
   Google Scholar
• GreeneKLAlbertsenPCBabaianRJProstate specific antigen best practice statement: 2009 updateJ Urol2013189Suppl 1S2S1123234625
   PubMed Web of Science ®Google Scholar
• AbuzalloufSDayesILukkaHBaseline staging of newly diagnosed prostate cancer: a summary of the literatureJ Urol20041716 Pt 12122212715126770
   PubMed Web of Science ®Google Scholar
• De NunzioCLeonardoCFrancoGWhen to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification toolWorld J Urol201331236536922576696
   PubMed Web of Science ®Google Scholar
• ChoiWWWilliamsSBGuXLipsitzSRNguyenPLHuJCOveruse of imaging for staging low risk prostate cancerJ Urol201118551645164921419444
   PubMed Web of Science ®Google Scholar
• PrasadSMGuXLipsitzSRNguyenPLHuJCInappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United StatesCancer201211851260126721823112
   PubMed Web of Science ®Google Scholar
• GarciaGJrRieraEVallsEBone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CTClin Nucl Med201338212012423334127
   PubMed Web of Science ®Google Scholar
• FuccioCCastellucciPSchiavinaRRole of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphyEur J Radiol2012818e893e89622621862
   PubMed Web of Science ®Google Scholar
• PicchioMSpinapoliceEGFallancaF[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphyEur J Nucl Med Mol Imaging2012391132621932120
   PubMed Web of Science ®Google Scholar
• FuccioCCastellucciPSchiavinaRRole of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphyAnn Nucl Med201024648549220544323
   PubMed Web of Science ®Google Scholar
• BalogovaSHuchetVEgrotCEffect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptakeClin Nucl Med201338320020223354033
   PubMed Web of Science ®Google Scholar
• PicchioMCastellucciPClinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapseTheranostics20122331331722448197
   PubMed Web of Science ®Google Scholar
• ScattoniVPicchioMSuardiNDetection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomyEur Urol200752242342917397992
   PubMed Web of Science ®Google Scholar
• JadvarHDesaiBJiLProspective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancerClin Nucl Med201237763764322691503
   PubMed Web of Science ®Google Scholar
• MosaviFJohanssonSSandbergDTWhole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinomaAJR Am J Roentgenol201219951114112023096187
   PubMed Web of Science ®Google Scholar
• JadvarHImaging evaluation of prostate cancer with (18) F-fluorodeoxyglucose PET/CT: utility and limitationsEur J Nucl Med Mol Imaging Epub2222013
   Web of Science ®Google Scholar